Skip To Main Content
Weijiayi Wang on Muck Rack

Weijiayi Wang

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Weijiayi

Contact Weijiayi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

|
By Jia Xu, Lin Liu, Wei Xie, Chenggong Li, Qiaolin Liu, Yun Pyo Kang, Yinqiang Zhang, Wenjing Luo, Chun Zhang, Chunyan Sun, YU HU, Heng Hui Mei, Liman Su, Weijiayi Wang, Zhongpei Huang
| Nature Verified
Abstract Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodepletion, with up to 3 months of follow-up.
Open in Who Shared Issue with article?
See all 1 articles